Bisindolylmaleimide VIII acetate

Research use only, not for human use.

Bisindolylmaleimide VIII acetate is a potent and selective PKC inhibitor (IC50: 158 nM for rat brain PKC).

Bisindolylmaleimide VIII acetate is a potent and selective PKC inhibitor (IC50: 158 nM for rat brain PKC). It has IC50s of 53, 195, 163, 213, and 175 nM for PKC-α, PKC-βI, PKC-βII, PKC-γ, PKC-ε, respectively.

Bisindolylmaleimide VIII acetate (Ro 31-7549 acetate; 5 μM; 8, 12 hours) dramatically increases TRA-8-induced cell death in time-dependent and TRA-8 dose-dependent manners. Bisindolylmaleimide VIII acetate (5 μM; 6 hours) significantly decreases procaspase-8 at 4 h and completely disappeares at 6 h after the combined treatment with TRA-8. Apoptosis Analysis Cell Line:1321N1 cells Concentration:5 μM Incubation Time:8, 12 hours Result: Dramatically increased TRA-8-induced cell death in time-dependent and TRA-8 dose-dependent manners.Western Blot Analysis Cell Line:1321N1 cells Concentration:5 μM Incubation Time:6 hours Result:Significantly decreased procaspase-8 at 4 h and completely disappeared at 6 h.

Bisindolylmaleimide VIII acetate (Ro 31-7549 acetate; 100 μg; IP; every other day for three doses) results in nearly complete tumor regression combined toTRA-8. The treatment with Bisindolylmaleimide VIII acetate alone does not induce significant tumor regression. Animal Model:6-8-week-old female NOD/SCID mice. Dosage:100 μg Administration:IP; every other day for three doses Result:Resulted in nearly complete tumor regression combined toTRA-8.

Ro 31-7549 acetate | Bis VIII acetate

Apoptosis

Apoptosis

Apoptosis|PKC|PKCα|PKCβ1|PKCβ2|PKCγ|PKCε

——

——

138516-31-1

458.51

C26H26N4O4

>98% (HPLC)

In Vitro:?DMSO : 250 mg/mL (545.24 mM)

O=C(C(C1=CN(CCCN)C2=C1C=CC=C2)=C3C4=CN(C)C5=C4C=CC=C5)NC3=O.CC(O)=O

——

(-20℃)

With Ice Pack

≥ 2 years